Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)

Allergan

Status: Completed

Conditions: Diabetic Macular Edema

Treatments: Drug: Dexamethasone intravitreal implant

Study type: Observational

Funder types: Industry

Identifiers

NCT03889444

CMO-MA-EYE-0564

Details and patient eligibility

About

A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1 January 2015 to 1 September 2017.

Enrollment: 141 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant received at least two Ozurdex® implants in the study eye to treat visual impairment due to DME
• First Ozurdex® implant injection occurred after 1 January 2015
• Participant was followed-up at the site for at least 12 months after the first Ozurdex® implant in the study eye

Exclusion criteria

• Participant received Ozurdex® implants as part or during a clinical study

Trial design

141 participants in 1 patient group

OZURDEX®

Description:

Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.

Treatment:

Drug: Dexamethasone intravitreal implant